Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ziihera
Pharma
Jazz’s Ziihera secures 2nd survival win in HER2+ stomach cancer
The magnitude of overall survival improvements has increased for both Ziihera regimens, either with or without BeOne’s Tevimbra, Jazz said.
Angus Liu
Aug 31, 2026 10:17am
Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer
Aug 25, 2026 11:06am
After trial fail, Teravance is bought out by Zymeworks for $929M
Jun 29, 2026 11:30am
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
Jan 6, 2026 3:25pm
Zymeworks pivots to become 'royalty-driven' drugmaker
Nov 18, 2025 8:25am
Jazz reviewing M&A deal options of 'various sizes,' CFO says
Feb 26, 2025 11:08am
